|
Health Equity in the COVID-19 Era: Understanding the Data and Strategies to Support Vulnerable Populations |
|
Enduring |
|
$0.00 |
|
Highlights from the 2022 Annual Meeting on Women's Cancer |
|
Enduring |
|
$0.00 |
|
Highlights from the 2023 Annual Meeting on Women's Cancer |
|
Enduring |
|
$195.00 |
|
Immunotherapy Part 1: Basics of Immune-Related Adverse Events |
|
Enduring |
|
$0.00 |
|
Immunotherapy Part 2: Common Controversies |
|
Enduring |
|
$0.00 |
|
Immunotherapy Part 3: Common Controversies and Remaining Questions |
|
Enduring |
|
$0.00 |
|
Immunotherapy Toxicities: A Society of Gynecologic Oncology Podcast |
|
Enduring |
|
$0.00 |
|
Infusion Confusion: COVID-19 and Anti-Cancer Treatments and Clinical Trial Considerations for Gynecologic Oncology Patients |
|
Enduring |
|
$0.00 |
|
Is Urology in House? Practical Management of Urologic Complications in Common Gyn Oncology Procedures On-Demand Webinar |
|
Enduring |
|
$35.00 |
|
Job Searches and Contract Negotiations: Career Considerations in the Time of COVID-19 |
|
Enduring |
|
$0.00 |
|
Keeping up with the Chemos Series: Lenvatinib/Pembrolizumab - Administration (Part 2) |
|
Enduring |
|
$0.00 |
|
Keeping up with the Chemos Series: Lenvatinib/Pembrolizumab - Follow up Monitoring Between Cycles (Part 3) |
|
Enduring |
|
$0.00 |
|
Keeping up with the Chemos Series: Lenvatinib/Pembrolizumab - Preparing to Give It (Part 1) |
|
Enduring |
|
$0.00 |
|
Keeping up with the Chemos Series: Mirvetuximab Soravtansine - Administration (Part 2) |
|
Enduring |
|
$0.00 |
|
Keeping up with the Chemos Series: Mirvetuximab Soravtansine - Follow up Monitoring Between Cycles (Part 3) |
|
Enduring |
|
$0.00 |
Facebook
Twitter
LinkedIn
Forward